Sleep Disorders and Gastroesophageal Reflux Disease (GERD)

Brief Summary

Official Title: “The Impact of Gastroesophageal Reflux Disease in Sleep Disorders: A Pilot Investigation of Rabeprazole, 20 mg Twice Daily for the Relief of GERD-Related Insomnia.”

This study will investigate Gastroesophageal Reflux Disease (GERD)as a cause of sleep disturbance. Patients with GERD may experience all or some of the following symptoms: stomach acid or partially digested food re-entering the esophagus (which is sometimes referred to as heartburn or regurgitation) and belching. Even very small, unnoticeable amounts of rising stomach acid may cause patients to wake up during the night.

This study will also investigate the effect of Rabeprazole, (brand name Aciphex) on patients with known insomnia. Rabeprazole is an FDA approved medication already marketed for the treatment of GERD.

  • Study Type: Interventional
  • Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Detailed Clinical Trial Description

Participants with known insomnia will undergo an overnight pH and sleep study. Those found to be eligible after the first sleep study (those with significantly poor sleep quality and no significant sleep apnea) will be started on 2 weeks 20 mgs, twice-a-day, rabeprazole. Upon completion of the 2 week course of rabeprazole, subjects will repeat the overnight pH and sleep studies. Upon completion of these studies, participation is complete.

Interventions Used in this Clinical Trial

  • Drug: Rabeprazole

Outcome Measures for this Clinical Trial

Primary Measures

  • The percentage of: subjects with non-OSA sleep disturbances who demonstrate esophageal reflux, night-time arousals which are accompanied by a reflux event.

Criteria for Participation in this Clinical Trial

Inclusion Criteria

1. English-speaking male or female subjects, 18-75 years of age. (Women must be two (2) years post-menopausal or surgically sterile. Women of childbearing potential or <1 year post-menopausal must be practicing an approved method of contraception and have a negative urine pregnancy test at screening.),

2. a six-month duration of insomnia,

3. sleep difficulty at least 3 nights per week, and a sleep study demonstrating > 10 arousals/hour for those aged < 45, and >15 for those who are 45 or older.

Exclusion Criteria

1. BMI > 30 or history of snoring (in order to decrease the prevalence of sleep apnea in the sample),

2. use of any proton pump inhibitor or H2 receptor antagonist within one week of undergoing initial sleep study,

3. previous acid-suppressing medication for sleep disturbances,

4. previous surgical antireflux procedure,

5. current medical therapy that includes digoxin or ketoconazole,

6. previous aerodigestive malignancy,

7. a previously diagnosed psychological or medical cause of insomnia (other than suspected GERD), and

8. inability or unwillingness to provide consent for the procedures.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 75 Years

Are Healthy Volunteers Accepted for this Clinical Trial: Accepts Healthy Volunteers

Clinical Trial Investigator Information

  • Lead Sponsor
    • University of North Carolina
  • Collaborator
    • Janssen Pharmaceutica N.V., Belgium
  • Overall Official(s)
    • Nicholas Shaheen, MD, MPH, Principal Investigator, UNC Gastroenterology


Clinical Trials content is provided directly by the US National Institutes of Health via and is not reviewed separately by Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: